NeuroPace (NASDAQ:NPCE) Upgraded at Wall Street Zen

NeuroPace (NASDAQ:NPCE) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Other research analysts have also recently issued reports about the stock. HC Wainwright increased their price target on shares of NeuroPace from $18.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Cantor Fitzgerald upgraded NeuroPace to a “strong-buy” rating in a report on Wednesday. JPMorgan Chase & Co. increased their target price on NeuroPace from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. UBS Group reissued a “buy” rating on shares of NeuroPace in a report on Wednesday, January 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NeuroPace in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.67.

NeuroPace Price Performance

NASDAQ:NPCE opened at $14.03 on Friday. The stock has a market capitalization of $472.39 million, a PE ratio of -21.26 and a beta of 1.86. NeuroPace has a 1-year low of $7.56 and a 1-year high of $18.98. The firm has a fifty day simple moving average of $15.54 and a 200 day simple moving average of $13.31. The company has a current ratio of 5.28, a quick ratio of 3.94 and a debt-to-equity ratio of 3.09.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. The company had revenue of $26.59 million for the quarter, compared to analyst estimates of $24.79 million. NeuroPace had a negative net margin of 21.47% and a negative return on equity of 105.67%. On average, research analysts expect that NeuroPace will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in NPCE. Ameritas Investment Partners Inc. increased its holdings in shares of NeuroPace by 83.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock worth $27,000 after purchasing an additional 1,118 shares during the period. Legal & General Group Plc boosted its stake in shares of NeuroPace by 86.0% in the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock valued at $30,000 after buying an additional 1,239 shares during the period. Quantbot Technologies LP bought a new stake in shares of NeuroPace in the second quarter valued at approximately $35,000. Quarry LP grew its position in NeuroPace by 94.9% during the third quarter. Quarry LP now owns 3,845 shares of the company’s stock worth $40,000 after buying an additional 1,872 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in NeuroPace by 72.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company’s stock worth $71,000 after acquiring an additional 2,668 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.